Christopher Gans, MD
Cardiovascular Disease · Ann Arbor, MINPI 1790986644
Payments from drug & device makers
Across 60 payments — averaging $1335.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$37K
- Novartis$26K
- Boehringer Ingelheim$12K
- AstraZeneca$5K
- Abbott$377
- Siemens Medical Solutions USA, Inc.$32
- plus $19 from 1 others
What the payments were for
- Speaking & faculty fees$30,20082%
- Travel & lodging$5,26014%
- Food & beverage$1,4744%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 41 | $36,505 |
| Novartis | 2 | $25,710 |
| Boehringer Ingelheim | 2 | $12,210 |
| AstraZeneca | 4 | $5,248 |
| Abbott | 8 | $377 |
| Siemens Medical Solutions USA, Inc. | 2 | $32 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYNDAQEL$36,042
How this compares
$80,101 in reported general payments places this provider in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 46 | $52,071 |
| EntrestoSacubitril/Valsartan | 39 | $43,550 |
| JardianceEmpagliflozin | 43 | $39,478 |
| XareltoRivaroxaban | 15 | $15,095 |
| Repatha SureclickEvolocumab | 20 | $13,092 |
| Bisoprolol Fumarate | 50 | $1,218 |
| Atorvastatin Calcium | 64 | $941 |
| Metoprolol Succinate | 55 | $940 |
| Rosuvastatin Calcium | 33 | $854 |
| Spironolactone | 43 | $513 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 13 | $443 |
| Torsemide | 29 | $402 |
| Spironolactone-HctzSpironolact/Hydrochlorothiazid | 11 | $305 |
| Chlorthalidone | 19 | $296 |
| Carvedilol | 25 | $293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $36,505 | $52,07146 claims |
| NovartisEntresto | $25,710 | $43,55039 claims |
| Boehringer IngelheimJardiance | $12,210 | $39,47843 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 760 cardiovascular disease providers in Michigan.
Other cardiovascular disease in Ann Arbor
- Stanley ChetcutiAnn Arbor$4.3M
- Victor MolesAnn Arbor$2.1M
- Marschall RungeAnn Arbor$1.8M
- Sara SaberiAnn Arbor$1.6M
- Vallerie McLaughlinAnn Arbor$1.4M
- David BachAnn Arbor$390K
- Bertram PittAnn Arbor$298K
- Adam HelmsAnn Arbor$236K
- Salim HayekAnn Arbor$229K
- Brahmajee NallamothuAnn Arbor$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.